Literature DB >> 20962094

Yeast-elicited cross-reactive antibodies to HIV Env glycans efficiently neutralize virions expressing exclusively high-mannose N-linked glycans.

Caroline Agrawal-Gamse1, Robert J Luallen, Bingfen Liu, Hu Fu, Fang-Hua Lee, Yu Geng, Robert W Doms.   

Abstract

The HIV envelope (Env) protein uses a dense coat of glycans to mask conserved domains and evade host humoral immune responses. The broadly neutralizing antibody 2G12, which binds a specific cluster of high-mannose glycans on HIV Env, shows that the glycan shield can also serve as a target for neutralizing antibodies. We have described a triple mutant Saccharomyces cerevisiae strain that expresses high-mannose glycoproteins that bind to 2G12. When used to immunize rabbits, this yeast elicits antibodies that bind to gp120-associated glycans but fail to neutralize virus. Here we sought to determine the reason for these discordant results. Affinity purification of sera over columns conjugated with three 2G12-reactive yeast glycoproteins showed that these proteins could adsorb 80% of the antibodies that bind to gp120 glycans. Despite binding to monomeric gp120, these mannose-specific antibodies failed to bind cell surface-expressed trimeric Env. However, when Env was expressed in the presence of the mannosidase inhibitor kifunensine to force retention of high-mannose glycans at all sites, the purified antibodies gained the abilities to bind trimeric Env and to strongly and broadly neutralize viruses produced under these conditions. Combined, these data show that the triple mutant yeast strain elicits antibodies that bind to high-mannose glycans presented on the HIV envelope, but only when they are displayed in a manner not found on native Env trimers. This implies that the underlying structure of the protein scaffold used to present the high-mannose glycans may be critical to allow elicitation of antibodies that recognize trimeric Env and neutralize virus.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20962094      PMCID: PMC3014190          DOI: 10.1128/JVI.01349-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.

Authors:  J R Mascola; G Stiegler; T C VanCott; H Katinger; C B Carpenter; C E Hanson; H Beary; D Hayes; S S Frankel; D L Birx; M G Lewis
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

2.  Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.

Authors:  T W Baba; V Liska; R Hofmann-Lehmann; J Vlasak; W Xu; S Ayehunie; L A Cavacini; M R Posner; H Katinger; G Stiegler; B J Bernacky; T A Rizvi; R Schmidt; L R Hill; M E Keeling; Y Lu; J E Wright; T C Chou; R M Ruprecht
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

3.  Comparing antigenicity and immunogenicity of engineered gp120.

Authors:  Suganya Selvarajah; Bridget Puffer; Ralph Pantophlet; Mansun Law; Robert W Doms; Dennis R Burton
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

4.  Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

Authors:  R Shibata; T Igarashi; N Haigwood; A Buckler-White; R Ogert; W Ross; R Willey; M W Cho; M A Martin
Journal:  Nat Med       Date:  1999-02       Impact factor: 53.440

5.  Polysaccharide mimicry of the epitope of the broadly neutralizing anti-HIV antibody, 2G12, induces enhanced antibody responses to self oligomannose glycans.

Authors:  D Cameron Dunlop; Camille Bonomelli; Fatma Mansab; Snezana Vasiljevic; Katie J Doores; Mark R Wormald; Angelina S Palma; Ten Feizi; David J Harvey; Raymond A Dwek; Max Crispin; Christopher N Scanlan
Journal:  Glycobiology       Date:  2010-02-24       Impact factor: 4.313

6.  Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.

Authors:  P W Parren; P A Marx; A J Hessell; A Luckay; J Harouse; C Cheng-Mayer; J P Moore; D R Burton
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

7.  Printed covalent glycan array for ligand profiling of diverse glycan binding proteins.

Authors:  Ola Blixt; Steve Head; Tony Mondala; Christopher Scanlan; Margaret E Huflejt; Richard Alvarez; Marian C Bryan; Fabio Fazio; Daniel Calarese; James Stevens; Nahid Razi; David J Stevens; John J Skehel; Irma van Die; Dennis R Burton; Ian A Wilson; Richard Cummings; Nicolai Bovin; Chi-Huey Wong; James C Paulson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-24       Impact factor: 11.205

8.  Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies.

Authors:  Yoshiaki Nishimura; Tatsuhiko Igarashi; Nancy Haigwood; Reza Sadjadpour; Ron J Plishka; Alicia Buckler-White; Riri Shibata; Malcolm A Martin
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

9.  Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

Authors:  M B Zwick; A F Labrijn; M Wang; C Spenlehauer; E O Saphire; J M Binley; J P Moore; G Stiegler; H Katinger; D R Burton; P W Parren
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

10.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.

Authors:  A Trkola; M Purtscher; T Muster; C Ballaun; A Buchacher; N Sullivan; K Srinivasan; J Sodroski; J P Moore; H Katinger
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

View more
  22 in total

Review 1.  Recent strategies targeting HIV glycans in vaccine design.

Authors:  Satoru Horiya; Iain S MacPherson; Isaac J Krauss
Journal:  Nat Chem Biol       Date:  2014-12       Impact factor: 15.040

Review 2.  Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.

Authors:  Peter D Kwong; John R Mascola; Gary J Nabel
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

3.  Antibodies elicited by yeast glycoproteins recognize HIV-1 virions and potently neutralize virions with high mannose N-glycans.

Authors:  Hong Zhang; Hu Fu; Robert J Luallen; Bingfen Liu; Fang-Hua Lee; Robert W Doms; Yu Geng
Journal:  Vaccine       Date:  2015-08-13       Impact factor: 3.641

Review 4.  How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?

Authors:  Per Johan Klasse; Rogier W Sanders; Andrea Cerutti; John P Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2011-05-20       Impact factor: 2.205

Review 5.  Designing synthetic vaccines for HIV.

Authors:  Alberto Fernández-Tejada; Barton F Haynes; Samuel J Danishefsky
Journal:  Expert Rev Vaccines       Date:  2015-03-31       Impact factor: 5.217

6.  Combinations of griffithsin with other carbohydrate-binding agents demonstrate superior activity against HIV Type 1, HIV Type 2, and selected carbohydrate-binding agent-resistant HIV Type 1 strains.

Authors:  Geoffrey Férir; Dana Huskens; Kenneth E Palmer; Daniel M Boudreaux; Michael D Swanson; David M Markovitz; Jan Balzarini; Dominique Schols
Journal:  AIDS Res Hum Retroviruses       Date:  2012-06-25       Impact factor: 2.205

7.  Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates.

Authors:  Kevin O Saunders; Nathan I Nicely; Kevin Wiehe; Mattia Bonsignori; R Ryan Meyerhoff; Robert Parks; William E Walkowicz; Baptiste Aussedat; Nelson R Wu; Fangping Cai; Yusuf Vohra; Peter K Park; Amanda Eaton; Eden P Go; Laura L Sutherland; Richard M Scearce; Dan H Barouch; Ruijun Zhang; Tarra Von Holle; R Glenn Overman; Kara Anasti; Rogier W Sanders; M Anthony Moody; Thomas B Kepler; Bette Korber; Heather Desaire; Sampa Santra; Norman L Letvin; Gary J Nabel; David C Montefiori; Georgia D Tomaras; Hua-Xin Liao; S Munir Alam; Samuel J Danishefsky; Barton F Haynes
Journal:  Cell Rep       Date:  2017-02-28       Impact factor: 9.423

8.  High-mannose glycan-dependent epitopes are frequently targeted in broad neutralizing antibody responses during human immunodeficiency virus type 1 infection.

Authors:  Christy L Lavine; Socheata Lao; David C Montefiori; Barton F Haynes; Joseph G Sodroski; Xinzhen Yang
Journal:  J Virol       Date:  2011-12-07       Impact factor: 5.103

9.  Crystal structure of the HIV neutralizing antibody 2G12 in complex with a bacterial oligosaccharide analog of mammalian oligomannose.

Authors:  Robyn L Stanfield; Cristina De Castro; Alberto M Marzaioli; Ian A Wilson; Ralph Pantophlet
Journal:  Glycobiology       Date:  2014-11-07       Impact factor: 4.313

Review 10.  Synthetic carbohydrate antigens for HIV vaccine design.

Authors:  Lai-Xi Wang
Journal:  Curr Opin Chem Biol       Date:  2013-12       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.